Skip to main content
Clinical Trials/NCT05257941
NCT05257941
Terminated
Phase 1

Randomized Prospective Study Comparison of Erector Spinae Plane Block and Intrathecal Opioid for Postoperative Analgesia After Laparoscopic Colorectal Surgery in an Enhanced Recovery Setting

Indiana University1 site in 1 country116 target enrollmentJanuary 27, 2022

Overview

Phase
Phase 1
Intervention
ESP Block
Conditions
Surgery
Sponsor
Indiana University
Enrollment
116
Locations
1
Primary Endpoint
24 Hour Cumulated Oral Morphine Equivalent (OME)
Status
Terminated
Last Updated
2 months ago

Overview

Brief Summary

This study is being done to compare 2 types of pain control methods and determine which is more effective postoperatively for laparoscopic colorectal surgery. Group 1 will receive an intrathecal (IT) injection in the back in which a small dose duramorph and bupivacaine will be placed into the spinal fluid. Group 2 will receive an erector spinae plane (ESP) block in which bupivacaine and decadron are injected near the nerves under a muscle in the back.

Detailed Description

All laparoscopic colorectal cases were scheduled by colorectal surgeons at IU Health University or Methodist Hospital and were identified using medical records. The subjects were contacted face-to-face prior to surgery. They were informed about the study and questions were answered. The potential subjects were given a copy of the informed consent form and authorization form. The subjects were contacted face-to-face in Pre-Operative Care Unit on the day of surgery and if they decided to participate, written consent was taken. In the Intrathecal group, intrathecal preservative free morphine (duramorph) 200 mcg with 7.5mg of hyperbaric bupivacaine was given for a patient 18-75 years of age and duramorph 150 mcg with 7.5mg of hyperbaric bupivacaine was given for a patient 76- 80 years of age. In the ESP group, a patient was given a bilateral ESP block at thoracic vertebrae level 10 (T10). This was placed under ultrasound using 30 ml of 0.25% bupivacaine and 4 mg of Decadron. Randomization will be performed using Research Randomizer. The primary investigator informed the person doing the regional techniques as to what group the patients were randomized to. Neither the patients and the research staff doing assessments will be blinded to the randomization.

Registry
clinicaltrials.gov
Start Date
January 27, 2022
End Date
August 29, 2024
Last Updated
2 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Amy McCutchan

Assistant Professor of Clinical Anesthesiology

Indiana University

Eligibility Criteria

Inclusion Criteria

  • Patients undergoing an elective laparoscopic colorectal procedure at Indiana University Hospital or Methodist Hospital
  • ASA Class 1, 2, 3 (American Society of Anesthesiologists physical status classification system)
  • Age 18 to 80 years (male or female)
  • BMI \< 40kg/m2
  • Desires regional anesthesia for postoperative pain control

Exclusion Criteria

  • Any contraindication for neuraxial analgesia or ESP block procedure
  • Contraindications for neuraxial analgesia include: Elevated intracranial pressure (except in cases of pseudo-tumor cerebri), infection at the site of injection, lack of consent from the patient, patient refusal, true allergy to any drug used in the spine, and uncorrected hypovolemia.
  • Contraindications for ESP block procedure include: Infection at the site of injection, patient refusal, true allergy to any of the drugs used in the block, and lack of patient consent.
  • Any patient undergoing a laparoscopic abdominoperineal resection.
  • Any physical, mental or medical conditions which, in the opinion of the investigators, may confound quantifying postoperative pain resulting from surgery.
  • Known true allergy to the study medications (morphine, bupivacaine, decadron, Tylenol, Celebrex)
  • Takes over 30 mg of oral morphine equivalents daily
  • Any history of substance abuse in the past 6 months
  • End stage liver disease, end stage renal disease
  • Body weight of \< 50 kg

Arms & Interventions

ESP Block

an erector spinae plane (ESP) block in which bupivacaine and decadron are injected near the nerves under a muscle in the back.

Intervention: ESP Block

IT Injection

an intrathecal (IT) injection in the back in which a small dose duramorph and bupivacaine will be placed into the spinal fluid

Intervention: IT Injection

Outcomes

Primary Outcomes

24 Hour Cumulated Oral Morphine Equivalent (OME)

Time Frame: 24 hours after surgery

24 hour cumulated oral morphine consumption (OME)

Secondary Outcomes

  • First Flatus(Duration of hospital stay up to 72 hours)
  • Oral Liquid(Duration of hospital stay up to 72 hours)
  • Oral Food(Duration of hospital stay up to 72 hours)
  • Oral Morphine Equivalents (OME)(72 hours after surgery)
  • Oral Morphine Equivalents (OME)(1 hour after surgery)
  • Oral Morphine Equivalents (OME)(12 hours after surgery)
  • Oral Morphine Equivalents (OME)(24 hours after surgery)
  • Oral Morphine Equivalents (OME)(48 hours after surgery)
  • Visual Analog Scale Pain Scores(1 hour after surgery)
  • Visual Analog Scale Pain Scores(12 hours after surgery)
  • Visual Analog Scale Pain Scores(24 hours after surgery)
  • Visual Analog Scale Pain Scores(48 hours after surgery)
  • Visual Analog Scale Pain Scores(72 hours after surgery)
  • First Ambulation(Duration of hospital stay up to 72 hours)
  • Hospital Length of Stay(Duration of hospital stay up to 7 days)
  • Patient's Satisfaction Scores(24 hours after surgery)
  • Patient's Satisfaction Scores(48 hours after surgery)
  • Number of Participants With Side Effects(Duration of hospital stay up to 72 hours)
  • Nausea(Duration of hospital stay up to 72 hours)

Study Sites (1)

Loading locations...

Similar Trials